Caas Capital Management LP Prometheus Biosciences, Inc. Transaction History

Caas Capital Management LP

  • $836 Million
  • Q3 2024

Shares

3 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2022

Feb 14, 2023
BUY
$36.06 - $117.21 $540,900 - $1.76 Million
15,000 New
15,000 $1.65 Million
Q2 2021

Aug 16, 2021
SELL
$16.8 - $29.65 $252,000 - $444,750
-15,000 Closed
0 $0
Q1 2021

May 17, 2021
BUY
$16.51 - $25.29 $247,650 - $379,350
15,000 New
15,000 $274,000

Others Institutions Holding RXDX

# of Institutions
2
Shares Held
29.6K
Call Options Held
0
Put Options Held
0
View Full List

About Prometheus Biosciences, Inc.

RXDX Quotes by TradingView
  • Ticker RXDX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 40,904,100
  • Description
  • Prometheus Biosciences, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of novel therapeutics and companion diagnostics products for the treatment of inflammatory bowel diseases (IBD). Its lead product includes PRA023, a humanized IgG1 monoclonal antibody (mAb), which is in Phase IIa clinical trial...
More about RXDX
Track This Portfolio

Track Caas Capital Management LP Portfolio

Follow Caas Capital Management LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Caas Capital Management LP, based on Form 13F filings with the SEC.

News

Stay updated on Caas Capital Management LP with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email